A framework for cost-effectiveness analysis from clinical trial data

被引:65
作者
O'Hagan, A
Stevens, JW
机构
[1] Univ Sheffield, Dept Probabil & Stat, Stat Serv Unit, Sheffield S3 7RH, S Yorkshire, England
[2] Astra Zeneca R&D Charnwood, Loughborough, Leics, England
关键词
Bayesian analysis; cost-effectiveness acceptability curve; log-normal distribution; net benefit; normal distribution; outcomes;
D O I
10.1002/hec.617
中图分类号
F [经济];
学科分类号
02 ;
摘要
We present a general Bayesian framework for cost-effectiveness analysis (CEA) from clinical trial data. This framework allows for very flexible modelling of both cost and efficacy related trial data. A common CEA technique is established for this wide class of models through linking mean efficacy and mean cost to the parameters of any given model. Examples are given in which efficacy may be measured as a continuous, binary, ordinal or time-to-event outcome, and in which costs are modelled as distributed normally, log-normally, as a mixture or non-parametrically. A case study is presented, illustrating the methodology and illuminating the role of prior information. Copyright (C) 2001 John Wiley & Sons, Ltd.
引用
收藏
页码:303 / 315
页数:13
相关论文
共 26 条
  • [11] Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio
    O'Hagan, A
    Stevens, JW
    Montmartin, J
    [J]. PHARMACOECONOMICS, 2000, 17 (04) : 339 - 349
  • [12] Bayesian cost-effectiveness analysis from clinical trial data
    O'Hagan, A
    Stevens, JW
    Montmartin, J
    [J]. STATISTICS IN MEDICINE, 2001, 20 (05) : 733 - 753
  • [13] A 1-year comparison of Turbuhaler vs pressurized metered-dose inhaler in asthmatic patients
    Pauwels, RA
    Hargreave, FE
    Camus, P
    Bukoski, M
    Stahl, E
    [J]. CHEST, 1996, 110 (01) : 53 - 57
  • [14] Cost-effectiveness analyses of salmeterol/fluticasone propionate combination product and fluticasone propionate in patients with asthma II:: Study methodologies
    Pieters, WR
    Lundbäck, B
    Johansson, G
    Palmqvist, M
    Price, MJ
    Sondhi, S
    Thwaites, RMA
    Yan, SK
    [J]. PHARMACOECONOMICS, 1999, 16 (Suppl 2) : 9 - 14
  • [15] Raikou Maria, 1998, BMJ, V317, P720
  • [16] Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study
    Sculpher, MJ
    Poole, L
    Cleland, J
    Drummond, M
    Armstrong, PW
    Horowitz, JD
    Massie, BM
    Poole-Wilson, PA
    Ryden, L
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2000, 2 (04) : 447 - 454
  • [17] Spiegelhalter DJ, 1999, WINBUGS VERSION 1 2
  • [18] Stinnett AA, 1998, MED DECIS MAKING, V18, pS68, DOI 10.1177/0272989X98018002S09
  • [19] A note on confidence intervals in cost-effectiveness analysis
    Tambour, M
    Zethraeus, N
    Johannesson, M
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 1998, 14 (03) : 467 - 471
  • [20] Tambour M, 1998, HEALTH ECON, V7, P143, DOI 10.1002/(SICI)1099-1050(199803)7:2<143::AID-HEC322>3.0.CO